
3 Pharma Formulations Exporter, Cardiac Care Hospitals Chain and Innerwear Brand Stocks With a Strong Future Roadmap: Marksans Pharma, Narayana Hrudayalaya and Dollar Industries
Marksans Pharma, Narayana Hrudayalaya and Dollar Industries: ROE of 11.3% to 17.8% and FY22 to FY26 revenue CAGR of 8.7% to 21.0%. Prices as of 18 Nov 2026.
Updated: 19 Nov 2026 • 2:42 pm
Posted by:

Quick Answer
The three export pharma, cardiac hospital and vest stocks to watch are Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Their return on equity ranges from 11.3% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.0%. Narayana Hrudayalaya leads on both return on equity at 17.8% and revenue growth at 21.0% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Export pharma, cardiac hospital and vest stocks give investors a way to track businesses that sit close to everyday demand in India. Marksans Pharma, Narayana Hrudayalaya and Dollar Industries cover a pharma formulations exporter, a cardiac care hospitals chain and an innerwear brand.
This list covers three export pharma, cardiac hospital and vest stocks with complete current figures: Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Export Pharma, Cardiac Hospital and Vest Stocks?
Export pharma, cardiac hospital and vest stocks are listed companies that make tablets, capsules and liquids for regulated overseas markets, run hospitals known for heart care and affordable surgery, and make and sell vests, briefs and thermal wear. Their earnings depend on export orders, patient numbers and apparel spending.
Export Pharma, Cardiac Hospital and Vest Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Marksans Pharma | 294.5 | 12,994 | 24.9 | 35.7 | 13.8 | 0.11 |
| Narayana Hrudayalaya | 1,891.3 | 35,603 | 43.6 | 59.6 | 17.8 | 1.29 |
| Dollar Industries | 251.41 | 1,489 | 13.3 | 35.2 | 11.3 | 0.31 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing export pharma, cardiac hospital and vest stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Export Pharma, Cardiac Hospital and Vest Stocks Have a Strong Roadmap in India?
Export pharma, cardiac hospital and vest stocks have a strong roadmap in India because steady demand for affordable medicines abroad, wider access to quality surgery and steady spending on everyday apparel keep widening the market for these companies.
- Pharma exports. Overseas buyers need affordable medicines.
- Cardiac hospitals. Families seek trusted surgeons.
- Innerwear. Households replace basics regularly.
Why Marksans Pharma Features Among These Export Pharma, Cardiac Hospital and Vest Stocks
Among the export pharma, cardiac hospital and vest stocks on this list, Marksans Pharma is a Mumbai-based drug maker that produces over-the-counter and prescription formulations at plants in India and sells them in the United Kingdom, the United States, Australia and other markets.
In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%.
Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7.
Roadmap: The company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
What to watch: Track export growth, new product approvals and plant utilisation.
Why Narayana Hrudayalaya Features Among These Export Pharma, Cardiac Hospital and Vest Stocks
Among the generic exporter, heart care chain and innerwear shares on this list, Narayana Hrudayalaya, widely known as Narayana Health, is a Bengaluru-based hospital group built around affordable cardiac care that now covers multiple specialities across India and also operates in the Cayman Islands.
The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6.
Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%.
Roadmap: Growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
What to watch: Keep an eye on occupancy in newly added beds and the payor mix between insurance and cash patients.
Why Dollar Industries Features Among These Export Pharma, Cardiac Hospital and Vest Stocks
Among the three companies on this list, Dollar Industries is a Kolkata-based innerwear and athleisure company that sells under brands such as Big Boss, Force NXT, Missy and Dollar Bigboss.
Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%.
In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P/E of 13.3, below the industry P/E of 35.2.
Roadmap: The company has a wide distribution network across the country and has widened its range into women's wear and athleisure. Brand extensions and a growing share of premium products support its plans.
What to watch: Track the growth in premium categories and the distributor network expansion.
Marksans Pharma vs Narayana Hrudayalaya vs Dollar Industries on Key Financials
The table below sets the three export pharma, cardiac hospital and vest stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Marksans Pharma | 1,533 | 3,033 | 18.6% | 420 | 13.8% |
| Narayana Hrudayalaya | 3,736 | 7,996 | 21.0% | 810 | 10.1% |
| Dollar Industries | 1,349 | 1,885 | 8.7% | 107 | 5.7% |
Narayana Hrudayalaya posts the highest return on equity in this group at 17.8%. Narayana Hrudayalaya combines the largest FY26 revenue at Rs 7,996 crore with the fastest revenue growth, a 21.0% compound annual rate. A useful habit with export pharma, cardiac hospital and vest stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Export Pharma, Cardiac Hospital and Vest Stocks
Every theme carries risks that deserve a check before any decision. For these export pharma, cardiac hospital and vest stocks, the main points are: Long-term generic exporter, heart care chain and innerwear shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Currency moves. Export earnings move with the rupee.
- Capacity ramp up. New hospitals take time to fill beds and reach full returns.
- Consumer spending. Sales follow festivals, incomes and consumer mood.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter export pharma, cardiac hospital and vest stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Export Pharma, Cardiac Hospital and Vest Stocks
Export pharma, cardiac hospital and vest stocks work best when investors track growth, valuation and return on equity side by side. Marksans Pharma, Narayana Hrudayalaya and Dollar Industries each have a clear plan to grow. Based on the 18 November 2026 close, Marksans Pharma trades at Rs 294.5, Narayana Hrudayalaya at Rs 1,891.3 and Dollar Industries at Rs 251.41. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these export pharma, cardiac hospital and vest stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track export pharma, cardiac hospital and vest stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are export pharma, cardiac hospital and vest stocks?
Ans. Export pharma, cardiac hospital and vest stocks are listed companies that make tablets, capsules and liquids for regulated overseas markets, run hospitals known for heart care and affordable surgery, and make and sell vests, briefs and thermal wear. Their earnings depend on export orders, patient numbers and apparel spending. This list looks at three of them, Marksans Pharma, Narayana Hrudayalaya and Dollar Industries, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which export pharma, cardiac hospital and vest stocks are covered in this list?
Ans. This list covers Marksans Pharma, Narayana Hrudayalaya and Dollar Industries. Based on the 18 November 2026 close, Marksans Pharma traded at Rs 294.5, Narayana Hrudayalaya at Rs 1,891.3 and Dollar Industries at Rs 251.41. Their return on equity ranges from 11.3% to 17.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.7% to 21.0%.
Why do export pharma, cardiac hospital and vest stocks have a strong future roadmap in India?
Ans. Export pharma, cardiac hospital and vest stocks have a strong roadmap in India because steady demand for affordable medicines abroad, wider access to quality surgery and steady spending on everyday apparel keep widening the market for these companies. The main drivers are as follows. Pharma exports. Overseas buyers need affordable medicines. Cardiac hospitals. Families seek trusted surgeons. Innerwear. Households replace basics regularly. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Marksans Pharma performed financially?
Ans. Revenue rose from Rs 1,533 crore in FY22 to Rs 3,033 crore in FY26, a compound annual growth rate of 18.6%. Net profit grew from Rs 187 crore in FY22 to Rs 420 crore in FY26, which works out to a compound annual growth rate of 22.5%. In the June 2026 quarter, revenue grew 38.5% year on year to Rs 866 crore. The company has a return on equity of 13.8%, a debt to equity ratio of 0.11 and a market capitalisation of Rs 12,994 crore. The stock trades at a P/E of 24.9, below the industry P/E of 35.7. Looking ahead, the company is adding capacity and new products for regulated markets, which supports export growth. A focus on over-the-counter products gives it steady, repeat demand.
How has Narayana Hrudayalaya performed financially?
Ans. Revenue rose from Rs 3,736 crore in FY22 to Rs 7,996 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 342 crore in FY22 to Rs 810 crore in FY26, which works out to a compound annual growth rate of 24.1%. The company has a return on equity of 17.8%, a debt to equity ratio of 1.29 and a market capitalisation of Rs 35,603 crore. The stock trades at a P/E of 43.6, below the industry P/E of 59.6. Looking ahead, growth is coming from bed additions across its hospital clusters, a rising share of higher-value specialities and an expanding insurance-led patient base. The group has a track record of running hospitals at high efficiency, which supports margins as scale builds.
How has Dollar Industries performed financially?
Ans. Revenue rose from Rs 1,349 crore in FY22 to Rs 1,885 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 52.5 crore in FY23 to Rs 107 crore in FY26, which works out to a compound annual growth rate of 26.9%. In the June 2026 quarter, revenue grew 1.5% year on year to Rs 406 crore, while net profit rose 20.4% to Rs 26.2 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 1,489 crore. The stock trades at a P/E of 13.3, below the industry P/E of 35.2. Looking ahead, the company has a wide distribution network across the country and has widened its range into women's wear and athleisure. Brand extensions and a growing share of premium products support its plans.
What risks should investors check before buying export pharma, cardiac hospital and vest stocks?
Ans. Investors should check a few risks before buying export pharma, cardiac hospital and vest stocks. Currency moves. Export earnings move with the rupee. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Consumer spending. Sales follow festivals, incomes and consumer mood. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of export pharma, cardiac hospital and vest stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

3 Dairy Products Company, Luxury Hotels Operator and Suiting Fabrics Maker Stocks With a Strong Future Roadmap: Heritage Foods, Indian Hotels Company and Siyaram Silk Mills
19 November 2026

3 Container Rail Logistics Company, Business Hotels Owner and Home Electricals Maker Stocks With a Strong Future Roadmap: Gateway Distriparks, SAMHI Hotels and V-Guard Industries
19 November 2026

3 Copper Ore Producer, Infrastructure Builder and Gold Jewellery Seller Stocks With a Strong Future Roadmap: Hindustan Copper, Larsen & Toubro and PN Gadgil Jewellers
19 November 2026

3 Agrochemicals Company, Cement Producer and CNC Machining Centres Maker Stocks With a Strong Future Roadmap: Insecticides India, JK Cement and Jyoti CNC Automation
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
3 Dairy Products Company, Luxury Hotels Operator and Suiting Fabrics Maker Stocks With a Strong Future Roadmap: Heritage Foods, Indian Hotels Company and Siyaram Silk Mills
3 Container Rail Logistics Company, Business Hotels Owner and Home Electricals Maker Stocks With a Strong Future Roadmap: Gateway Distriparks, SAMHI Hotels and V-Guard Industries
3 Copper Ore Producer, Infrastructure Builder and Gold Jewellery Seller Stocks With a Strong Future Roadmap: Hindustan Copper, Larsen & Toubro and PN Gadgil Jewellers
3 Agrochemicals Company, Cement Producer and CNC Machining Centres Maker Stocks With a Strong Future Roadmap: Insecticides India, JK Cement and Jyoti CNC Automation
3 Tractors Maker, Textile Specialty Chemicals Maker and Defence Optics Maker Stocks With a Strong Future Roadmap: Escorts Kubota, Rossari Biotech and Paras Defence and Space Technologies

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





